Investigational new drugs · 2010
Anti-leukemic activity of dasatinib in both p53(wild-type) and p53(mutated) B malignant cells.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bosco Raffaella, Rabusin Marco, Voltan Rebecca, Celeghini Claudio, Corallini Federica, Capitani Silvano, Secchiero Paola
Аннотация
The multi-kinase inhibitor dasatinib induced a variable but significant decrease of viability in both p53(wild-type) (EHEB, JVM-2, JVM-3) and p53(mutated) (MEC-1, MEC-2, BJAB) prolymphocytic B leukemic cells, due to a combination of cell cycle block in G1 and apoptosis. Antibody phospho-kinase array analysis revealed that dasatinib inhibited the phosphorylation of various kinases, including ERK1/2 and p38/MAPK as well as of STAT3 transcription factors, in both p53(wild-type) and p53(mutated) cells. Therefore, dasatinib might offer a novel therapeutic strategy not only for p53(wild-type), but also for p53(mutated) B malignancies that have the worst prognosis and urgently need innovative therapeutic approaches.
Предметные рубрики MeSH
Antineoplastic AgentsApoptosisB-LymphocytesCell Line, TumorCell SurvivalDasatinibG1 Phase Cell Cycle CheckpointsGranulocyte Precursor CellsHumansLeukemia, Prolymphocytic, B-CellMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3MutationPhosphorylationProtein Kinase InhibitorsPyrimidinesSTAT3 Transcription FactorThiazolesTime FactorsTumor Suppressor Protein p53p38 Mitogen-Activated Protein Kinases